Compare MXCT & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXCT | NNNN |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.8M | 154.1M |
| IPO Year | 2021 | 2023 |
| Metric | MXCT | NNNN |
|---|---|---|
| Price | $1.38 | $3.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.11 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 31.3K |
| Earning Date | 11-10-2026 | 12-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,026,000.00 | N/A |
| Revenue This Year | $4.77 | N/A |
| Revenue Next Year | $10.06 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.64 | $3.09 |
| 52 Week High | $1.80 | $44.73 |
| Indicator | MXCT | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 38.09 |
| Support Level | $1.02 | $3.21 |
| Resistance Level | $1.54 | $4.43 |
| Average True Range (ATR) | 0.14 | 0.37 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 70.41 | 5.86 |
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).